Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi(FX Palo Alto Laboratory), Edgar G. Engleman(Stanford Medicine)
Annual Review of Pathology Mechanisms of Disease
November 16, 2020
Cited by 2,162
Related Papers
Neutrophil-activating therapy for the treatment of cancer
|Cancer Cell|2023|196
Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
|American Journal of Transplantation|2012|190
B-1a Lymphocytes Attenuate Insulin Resistance
|Diabetes|2014|109
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer
|Journal of Clinical Investigation|2024|41
Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity
|JCI Insight|2016|27